Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.
Thomson Pharma will offer drug related clinical trial intelligence from registries, publications, press releases, conferences, and other sources across all therapeutic areas. It includes some of the most advanced searching capabilities on the market, enabling identification of trials based on over twenty criteria that are individually indexed by experts. This includes not only trial criteria such as drug, phase and recruitment status, but also scientific criteria such as mechanism of action, target and biomarker.
"We are proud to be the first to integrate drug pipeline content with robust clinical trial content in a single competitive intelligence solution," said Wendy Hamilton, vice president of product strategy at Thomson Reuters. "This not only addresses our customers' needs for increased efficiency and new competitive insights, but also ensures that Thomson Pharma will remain the most comprehensive single solution for pharmaceutical competitive intelligence on the market."
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth